Clinical trials located in

Córdoba

Córdoba city is located in Spain. Currently, 20 clinical trials are being conducted in this city.

Córdoba, located in southern Spain, is a city rich in history and culture. It was a significant Roman city and later the capital of the Islamic Emirate and then Caliphate of Córdoba. The city’s historic center is a UNESCO World Heritage Site, notable for the Mosque-Cathedral of Córdoba, an architectural marvel that symbolizes the diverse religious history of Spain. Córdoba is also famous for its traditional courtyards or “patios,” which are beautifully decorated with flowers and plants, celebrating the annual Festival de los Patios.

  • CT-EU-00121560

    Study of the safety and effectiveness of GLSI-100 in patients with HER2-positive breast cancer

    The study concerns the treatment of patients with HER2/neu-positive breast cancer. Treatment will include GLSI-100 immunotherapy and comparison to placebo. GLSI-100 consists of GP2 peptide and GM-CSF, protein substances that are designed to strengthen the body’s immune response, i.e. natural protection against diseases.

    The aim of this study is to determine how effective and safe GLSI-100 therapy is compared to placebo in preventing breast cancer recurrence after standard treatment. The study is aimed at people at high risk of disease recurrence who have completed both preoperative and postoperative therapy based on trastuzumab, a drug used to treat breast cancer.

    The study will assess invasive breast cancer-free survival (i.e. the time from the first dose of the drug to the moment of disease recurrence or death from any cause), invasive disease-free survival (i.e. the time from the first dose of the drug to the moment of any disease recurrence or new cancer), remote disease (i.e. time until disease recurrence in a place other than the breast or death).

    The study also includes an assessment of the participants’ quality of life both at the beginning and over the next 36 months, as well as an analysis of the body’s immune response to treatment.

  • Study on the effectiveness and safety of DMX-200 for FSGS patients using ARB

    Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disease where some parts of the kidneys become scarred, leading to kidney damage and protein loss in urine. This study involves a therapy using an experimental drug named DMX-200 (also known as repagermanium), which, when taken with a type of medication called an Angiotensin II Receptor Blocker (ARB), aims to halt the inflammation that contributes to chronic kidney disease.

    The study is designed to assess how well DMX-200 works and how safe it is in treating people with FSGS. It will compare the effects of DMX-200 with a placebo over a period of 104 weeks (about 2 years). Patients will be given either DMX-200 in capsule form to take twice daily or a placebo. Given the rarity of FSGS, the study will include both adults and adolescents aged 12 to 17 years.

    The study will start with a screening period to ensure all necessary assessments are completed. This will be followed by the main treatment phase, lasting 104 weeks. After this, there will be a 4-week follow-up period without treatment to observe any changes. Patients who complete this double-blind period and might benefit from continued treatment will enter an open-label extension phase. During this phase, participants will receive DMX-200 for an additional 2 years, also followed by a 4-week off-treatment period for further observation.

    The goal is to determine the effectiveness and long-term safety of DMX-200 for treating FSGS. The study aims to improve understanding and develop new treatments for this challenging kidney condition.

    • DMX-200
    • placebo
  • Study on the effectiveness and safety of M281 in adults with warm Autoimmune Hemolytic Anemia

    The study focuses on Warm Autoimmune Hemolytic Anemia (wAIHA), a condition where the immune system mistakenly destroys red blood cells. This leads to symptoms like fatigue, weakness, and jaundice (yellowing of the skin or eyes). The trial examines the effects of a therapy named M281 (Nipocalimab). The purpose of the study is to evaluate the efficacy and safety of M281. Patients participating in the study will receive either M281 or a placebo. It aims to compare improvements in health and monitor any side effects.

    The study structure is as follows:

    Double-blind period: This lasts for 24 weeks, where participants will be randomly assigned to one of three groups. One group will receive M281 every 4 weeks, alternating with a placebo every 4 weeks. Another group will receive M281 every 2 weeks, and the third group will receive a placebo every 2 weeks.

    Open-label extension period: This phase extends for 144 weeks, where all participants will receive M281, either every 2 weeks or every 4 weeks.

    Participants will be monitored for 8 weeks after the last dose to check for any ongoing effects of the treatment. The study aims to provide comprehensive information about the effectiveness and safety of M281 in treating wAIHA.

    • M281
    • placebo
  • Study on the safety and effectiveness of Setanaxib for Alport Syndrome patients

    The purpose of this study is to learn about the safety and tolerability of a drug called setanaxib in patients with Alport syndrome, when added to their standard of care treatment. The study will compare how safe setanaxib is when compared to a placebo. Participants will be asked about any side effects they experience at each study visit. Additionally, tests in blood, urine, and other examinations will be used to assess the safety of setanaxib. The study will also measure how well setanaxib works in comparison to a placebo by measuring urine protein and certain markers in the blood and urine. The concentration of setanaxib in the blood will also be measured throughout the course of the study.

    This is a Phase 2a, randomized, double-blind, placebo-controlled study. This means that participants will be randomly assigned to receive either setanaxib or a placebo, and neither the participants nor the researchers will know who is receiving which treatment.

    • placebo
    • Setanaxib
  • Study of ustekinumab and guselkumab in young patients with juvenile psoriatic arthritis

    This here clinical trial is aimin’ to study two different medicines, ustekinumab and guselkumab, for treatin’ a condition called juvenile psoriatic arthritis. This is a type of arthritis that affects young’uns and causes joint pain, swellin’, and stiffness.

    The study will have two groups, one group takin’ ustekinumab and the other takin’ guselkumab. These medicines work by targetin’ certain proteins in the body that cause inflammation, which is the root cause of the arthritis symptoms.

    The main goal of the study is to see how well these medicines work in reducin’ the symptoms of juvenile psoriatic arthritis, like joint pain and swellin’. The study will also look at how the body handles these medicines and if they cause any side effects.

    The study will last for about a year and a half, with regular check-ups and assessments to monitor the participants’ progress.

    • Ustekinumab
    • Guselkumab
  • Study on combining two drugs – Fianlimab and Cemiplimab in patients with previously untreated melanoma

    This study examines two drugs, fianlimab and cemiplimab, given together for the treatment of melanoma. The main goal is to see how effective this drug combination is in treating melanoma compared with pembrolizumab, which is already approved for the treatment of melanoma in adults. The study will also look at whether there are any differences in the effects of these experimental drugs in adolescents and adults.

    Scientists also want to learn about other key issues: what side effects may occur from taking these experimental drugs, how much of the drugs enter the bloodstream over time, and whether the body produces antibodies to the drugs that could make them less effective or cause side effects. They will also check whether taking medications improves patients’ quality of life. Fianlimab and cemiplimab will be administered by intravenous infusion, and pembrolizumab will be administered by intravenous infusion.

    • placebo
    • Fianlimab
    • Cemiplimab
    • Pembrolizumab
  • Efficacy and safety study of rosnilimab in moderate to severe rheumatoid arthritis

    This study will evaluate the effectiveness and safety of Rosnilimab in patients with moderate to severe rheumatoid arthritis. Rosnilimab is an antibody that activates the PD-1 receptor, also known as ANB030. Patients will be randomly assigned to receive Rosnilimab or placebo.

    The main aim of the study is to assess changes in the 28-Joint Disease Activity Index based on the concentration of C-reactive protein (DAS28-CRP) after 12 weeks of treatment. DAS28-CRP is a validated tool that assesses disease activity based on the number of painful and swollen joints and the concentration of C-reactive protein in the blood. A reduction in DAS28-CRP indicates an improvement in the patient’s condition.

    This study aims to test whether Rosnilimab is effective and safe in the treatment of rheumatoid arthritis. If the results are promising, this drug could become a new treatment option for patients suffering from this disease.

    • placebo
    • Rosnilimab
  • ARTEMIS study: Protecting kidney health in heart surgery patients with Ravulizumab

    The ARTEMIS study aims to find a new way to protect people with chronic kidney disease (CKD) undergoing heart surgery requiring the use of a heart-lung machine, also known as cardiopulmonary bypass (CPB). The main aim of this study is to see if a single dose of a drug called ravulizumab given intravenously can reduce the risk of serious kidney problems after surgery, compared with a placebo. Kidney issues are grouped under serious adverse events, and investigators will monitor them for up to 90 days after surgery. The study is carefully controlled and participants will not know whether they are receiving ravulizumab or a placebo to ensure the results are unbiased. This is an important test for people with chronic kidney disease undergoing heart surgery because it may lead to better outcomes and a lower risk of kidney damage after surgery.

    • placebo
    • Ravulizumab
  • CT-EU-00053821

    Testing the safety and efficacy of Rapcabtagene autoleucel in combination with ibrutinib for the treatment of various leukemia

    This study is looking at a new drug called rapcabtagene autoleucel in people with different types of blood cancer. The treatment is divided into two phases. In phase I, the study is testing the safety and efficacy of the new treatment in three different patient groups. The first group is adults with CLL/SLL, a type of blood cancer that has not shown a good response to the drug ibrutinib. The second group is adults with DLBCL, another type of blood cancer, who have failed at least two other treatments and who are unable or unwilling to undergo a stem cell transplant. The third group is adults with ALL, another type of blood cancer, who have not responded to other treatments. Phase II extends Phase I, focusing on the two main groups. The aim of this part is to obtain additional information on the efficacy of the new treatment. The aim of both phases is to determine the best dose of rapcabtagene autoleucel, to see how safe it is and how well it works against these tumors. After the treatment part of the study is completed, patients will be followed up for at least two years to monitor their health status and the long-term effects of the treatment.

    • Rapcabtagene autoleucel/YTB323
    • Ibrutinib
  • Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    • Enzalutamide/Xtandi
    • Darolutamide/Nubequa
    • Abiraterone Acetate/Zytiga
    • Saruparib
  • Examining capivasertib and docetaxel in advanced prostate cancer

    This trial is testing a new potential treatment for a type of advanced prostate cancer. The study will compare two combinations: one with Capivasertib and another called Docetaxel, compared with placebo (a dummy tablet with no medical effect) and Docetaxel. In addition, each study participant will receive steroid treatment and another therapy called androgen deprivation therapy. The main goal of this study is to demonstrate whether Capivasertib + Docetaxel extends patients’ lives more than placebo + Docetaxel. They will also be monitored for the time it takes for the cancer to show signs of growth again, for the pain to increase or for urinary symptoms to worsen.

    • Capivasertib
    • Docetaxel
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    • Prednisone
    • Vincristine
    • Doxorubicin
    • Epcoritamab
    • Cyclophosphamide
    • Rituximab
  • Ceralasertib & durvalumab vs docetaxel in advanced lung cancer study

    This is an open-label study titled LATIFY, which means everyone will know the type of treatment they are receiving. The study team is looking into a specific type of lung cancer, called Non-Small Cell Lung Cancer (NSCLC) which did not get better after previous treatments. Two treatments will be tested, a new combination of ceralasertib plus durvalumab, compared to a commonly used treatment, docetaxel. Doctors will track participants’ health over time to see which treatment helps people live longer. Understanding the results will help doctors responsibly give the best treatment for patients with this type of lung cancer.

    • Ceralasertib
    • Durvalumab
    • Docetaxel
  • Comparing a new treatment with standard care for advanced colorectal cancer

    This research study is for people suffering from a type of bowel cancer that has spread to other parts of the body, known as ‘metastatic colorectal cancer’. The purpose of the study is to compare a new combination of medications against the regular treatments that are already in use. Patients participating in the study will be placed into two groups: one group will receive the standard treatment, and the other group will try a new combination of drugs (tucatinib, trastuzumab, and 5-Fluorouracil, leucovorin,,oxaliplatin). This study will also help to understand the side effects, which are any unexpected symptoms or changes that can occur when taking these medications. Ultimately, the goal of this study is to help learn more about which treatment is more effective in delaying the progression of the disease and improving the patients’ quality of life.

    • levoleucovorin
    • leucovorin
    • Fluorouracil
    • Bevacizumab
    • Cetuximab
    • Tucatinib
    • Oxaliplatin
    • Trastuzumab
  • Advanced lung cancer treatment: comparing osimertinib with standard chemotherapy

    In this extended study, researchers are evaluating two treatment approaches for non-small cell lung cancer (NSCLC), focusing on patients who have experienced disease progression extracranially after initial treatment with osimertinib. The study aims to compare the efficacy and safety of chemotherapy combined with osimertinib versus chemotherapy combined with a placebo. Patients are randomly assigned to one of two groups. Group A receives osimertinib daily along with two chemotherapy drugs (cisplatin or carboplatin and pemetrexed) for four 21-day cycles. After these cycles, they continue taking osimertinib with maintenance pemetrexed. Group B follows a similar protocol but with a placebo instead of osimertinib. The study’s objective is to understand which treatment method better helps patients with this specific cancer profile, considering factors like genetic mutations and the presence of brain metastases. By observing the treatment’s impact on disease progression and patient safety, the researchers hope to gain insights that could improve NSCLC treatment strategies.

    • AZD9291 (Osimertinib)
    • Cisplatin
    • Carboplatin
    • Pemetrexed
  • Testing zimberelimab and domvanalimab with chemotheraphy for lung cancer

    This clinical trial explores the effectiveness of two new medicines, zimberelimab and domvanalimab, in tandem with chemotherapy for patients with untreated metastatic non-small cell lung cancer. The study’s main goal is to compare the impact and success of this combination treatment versus a control group receiving pembrolizumab along with chemotherapy. The hopeful outcome of the trial is to identify whether the new combination of drugs can provide enhanced benefits for the involved patients. Regular health monitoring will occur during the trial to ensure patient safety.

    • Pemetrexed
    • Nab-paclitaxel
    • Paclitaxel
    • Cisplatin
    • Carboplatin
    • Pembrolizumab
    • Domvanalimab
    • Zimberelimab
  • Advanced lung cancer study: exploring osimertinib & savolitinib

    This clinical trial evaluates a combination of two drugs, osimertinib and savolitinib, for treating advanced non-small cell lung cancer (NSCLC) in patients who have previously been treated with osimertinib. The study aims to determine if this combination can overcome resistance to treatment and improve patient outcomes. Participants will receive either the drug combination or a placebo, and the trial will assess the effectiveness and safety of the treatment.

    • savolitinib
    • Osimertinib
  • Testing new treatment for Geographic Atrophy treatment

    This research study pertains to a condition affecting the eyes known as Geographic Atrophy (GA), stemming from the aging process (Age-related Macular Degeneration). The investigation aims to assess the potential efficacy of a new drug (JNJ-81201887), administered through intraocular injection, in improving the aforementioned condition. A comparative analysis will be conducted between individuals receiving the drug and those subjected to a placebo procedure (a simulated intervention lacking an actual drug). Specialized photographs will be taken to quantify any alterations in the condition over an 18-month period. Additionally, observations will be made regarding changes in distant visual acuity, reading ability, and the requirement for aids during these activities over time. Ultimately, the study will examine the impact of the eye condition on daily activities.

    • JNJ-81201887- new potential medication for Geographic Atrophy
    • Prednisone
    • Triamcinolone
  • Study on the safety and efficacy of a new medicine on various lupus types

    This study is for people with different types of lupus. The main reason for the study is to learn if a new drug named BMS-986326 is safe for people and how their bodies react to it. The study begins by administering small doses of the drug to participants. If these small doses are deemed safe, progressively larger doses are administered. This process is repeated until identifying the largest dose that remains safe and effective. The drug is administered to participants intravenous or via a subcutaneous injection. This is crucial as the goal is to determine the optimal administration method for this drug in people.

    • BMS-986326- new potential medication for autoimmune disorders and cancer
  • Testing the effect of the new drug on Crohn’s Disease

    This study is exploring a new medication for Crohn’s disease, an ailment of the gut. The medication, known as BI 706321, is given alongside another medication called Ustekinumab that is already used to treat Crohn’s. The trial is conducted to see if this combination helps to manage the disease better. Participants will be split into two groups. One group will be given the new medication and the other will receive a placebo, alongside Ustekinumab. Participating in this study will last for 1 year. During this time, participants will have about 13 visits to the clinic. Some visits will involve a colonoscopy where doctors look at the intestine’s condition. Their findings will help doctors understand if the new treatment is working.

    • BI 706321- new potential medication for Crohn’s disease
    • ustekinumab

See more clinical trials in other cities in Spain:

.